

# Three scientists share \$500,000 prize for work on cancer therapy

15 August 2018



This undated photo provided by the National Cancer Institute shows Dr. Steven A. Rosenberg, M.D., Ph.D., winner of the 2018 Albany Medical Center's Prize in Medicine and Biomedical Research. (Center for Cancer Research, National Cancer Institute via AP)

Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a \$500,000 medical prize.

The recipients of the annual Albany Medical Center Prize in Medicine and Biomedical Research,

announced Wednesday, are being recognized for their studies of the immune system that have led to innovative treatments for cancer, HIV and other diseases.

They are James Allison of the University of Texas MD Anderson Cancer Center; Dr. Carl June of the Perelman School of Medicine, University of Pennsylvania; and Dr. Steven Rosenberg of the National Cancer Institute. They'll receive the award at a ceremony Sept. 26 in Albany, New York.

"Their research has given hope to many who otherwise faced a certain death sentence, and has inspired the work of hundreds of other researchers to investigate new pathways for treatment," said Dr. Vincent Verdile, dean of Albany Medical College. "Their impact on the development of [cancer immunotherapy](#) - and where it goes from here - is unsurpassed."

Immunotherapy harnesses the power of the immune system to attack cancer cells and tumors. In the 1980s, Rosenberg theorized that stimulating white [blood cells](#) called T cells could provoke immune reactions. His work led to the first [immunotherapy drug](#) approved by the U.S. Food and Drug Administration to treat cancer in 1992.




This undated photo provided by the University of Texas MD Anderson Cancer Center shows James P. Allison, Ph.D., of the University of Texas MD Anderson Cancer Center, winner of the 2018 Albany Medical Center's Prize in Medicine and Biomedical Research. (University of Texas MD Anderson Cancer Center via AP)

Former President Jimmy Carter credited the new immune therapy drug Keytruda with shrinking his brain tumors in 2015. The drug, developed using an approach pioneered by Allison, is among a new class of genetically engineered antibody-based medicines that are transforming treatment for several kinds of cancer with drugs that are often less toxic than chemotherapy.

June has led groundbreaking work in developing CAR-T cell therapies, which alter a patient's own blood cells to turn them into specialized cancer

killers. CAR-T therapy became the first FDA-approved personalized cellular therapy for cancer in 2017 with the approval of Kymriah to treat certain pediatric and young adult leukemia patients.



This undated photo provided by Penn Medicine shows Carl June, M.D., of the Perelman School of Medicine, University of Pennsylvania, winner of the 2018 Albany Medical Center's Prize in Medicine and Biomedical Research. (Penn Medicine via AP)

© 2018 The Associated Press. All rights reserved.

APA citation: Three scientists share \$500,000 prize for work on cancer therapy (2018, August 15) retrieved 29 August 2022 from <https://medicalxpress.com/news/2018-08-scientists-prize-cancer-therapy.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*